sarepta therapeutics nasdaq

News

Sarepta Shares Sink

Sarepta to continue Elevidys shipments despite FDA request to halt

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after patient deaths. Read more here.

InvestorsHub on MSN · 2d

Sarepta Shares Sink After Patient Death in Early-Stage Gene Therapy Trial

· 1d

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

GEN - Genetic Engineering and Biotechnology News8h

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

3don MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

Sarepta Therapeutics Provides Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

1don MSN

Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results